Vir Biotechnology Inc

NASDAQ:VIR   3:47:00 PM EDT
40.93
+4.93 (+13.69%)
Regulatory, Mergers / Acquisitions

GSK, Vir Say COVID-19 Antibody Drug Met Main Goal In Late-Stage Study

Published: 11/12/2021 12:14 GMT
Vir Biotechnology Inc (VIR) - Glaxosmithkline Plc - Phase Iii Im Administration Data for Sotrovimab.
Gsk - Primary Endpoint Met in Comet-tail Phase Iii Trial.
Gsk - Comet-tail Phase Iii Data Demonstrated That Intramuscular Administration of Sotrovimab Was Non-inferior.
Gsk - in Addition, There Were Low Rates of Serious Adverse Events and Grade 3-4 Adverse Events.
Gsk - Intramuscular Administration of Sotrovimab Was Non-inferior and Offered Similar Efficacy to Intravenous Administration for High-risk Populations.
Gsk - Trial Enrolled Participants During Delta Variant Wave of Pandemic in Us.
Gsk - There Were Low Rates of Serious Adverse Events and Grade 3-4 Adverse Events (≤1% in Both Arms, for Both Measures) Observed in Headline Data.
Gsk - Ongoing Discussions With FDA Regarding Existing Emergency Use Authorization for Sotrovimab.
Gsk - Companies Plan to Progress Regulatory Submissions Globally.
Gsk - Final Comet-ice Trial Results Demonstrated 79% Reduction in Hospitalisation and Death at Day 29 Versus Placebo.